• Plans to deploy net proceeds from a USD 23.5 million registered direct offering into working capital, investments, acquisitions, general corporate purposes.
• Closing targeted on or about July 23, 2026, subject to customary conditions.
• Positioning strategy centers on an AI-powered platform for managing multiple chronic conditions, supported by existing institutional investors and a new fundamental investor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DarioHealth Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220800PR_NEWS_USPR_____LN10027) on July 22, 2026, and is solely responsible for the information contained therein.